scholarly journals Evaluation of chitosan based vaginal bioadhesive gel formulations for antifungal drugs

2014 ◽  
Vol 64 (2) ◽  
pp. 139-156 ◽  
Author(s):  
Zeynep Ay Şenyiğit ◽  
Sinem Yaprak Karavana ◽  
Bayri Eraç ◽  
Özge Gürsel ◽  
Mine Hoşgör Limoncu ◽  
...  
Keyword(s):  
Molecular Mass ◽  
Antifungal Agents ◽  
Antifungal Drugs ◽  
Miconazole Nitrate ◽  
Different Types ◽  
Molecular Masses ◽  
Distribution Studies ◽  
Gel Formulations ◽  
Econazole Nitrate

Abstract The aim of the present study was to evaluate chitosan as a vaginal mucoadhesive gel base for econazole nitrate and miconazole nitrate. To this aim, different types of chitosan with different molecular masses and viscosity properties [low molecular mass chitosan (viscosity: 20,000 mPa s), medium molecular mass chitosan (viscosity: 200,000 mPa s), high molecular mass chitosan (viscosity: 800,000 mPa s)] have been used. First, rheological studies were conducted on chitosan gels. Mechanical, syringeability and mucoadhesive properties of chitosan gels were determined. Release profiles of econazole nitrate and miconazole nitrate from chitosan gels were obtained and evaluated kinetically. In addition, anticandidal activities of formulations were determined. Finally, vaginal retention of chitosan gels in rats was evaluated by in vivo distribution studies. Based on the results, it can be concluded that gels prepared with medium molecular mass chitosan might be effectively used for different antifungal agents in the treatment of vaginal candidiosis, since it has high mucoadhesiveness, suitable mechanical and release properties with good vaginal retention

scholarly journals Marine Bioactive Compounds against Aspergillus fumigatus: Challenges and Future Prospects

Antibiotics ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 813
Author(s):  
Chukwuemeka Samson Ahamefule ◽  
Blessing C. Ezeuduji ◽  
James C. Ogbonna ◽  
Anene N. Moneke ◽  
Anthony C. Ike ◽  
...  
Keyword(s):  
Mortality Rate ◽  
Invasive Aspergillosis ◽  
Aspergillus Fumigatus ◽  
Bioactive Compounds ◽  
Antifungal Agents ◽  
Antifungal Drugs ◽  
Marine Resources ◽  
Future Prospects ◽  
Speed Up

With the mortality rate of invasive aspergillosis caused by Aspergillus fumigatus reaching almost 100% among some groups of patients, and with the rapidly increasing resistance of A. fumigatus to available antifungal drugs, new antifungal agents have never been more desirable than now. Numerous bioactive compounds were isolated and characterized from marine resources. However, only a few exhibited a potent activity against A. fumigatus when compared to the multitude that did against some other pathogens. Here, we review the marine bioactive compounds that display a bioactivity against A. fumigatus. The challenges hampering the discovery of antifungal agents from this rich habitat are also critically analyzed. Further, we propose strategies that could speed up an efficient discovery and broaden the dimensions of screening in order to obtain promising in vivo antifungal agents with new modes of action.

scholarly journals In Vitro and In Vivo Experimental Activities of Antifungal Agents against Fusarium solani

1999 ◽  
Vol 43 (5) ◽  
pp. 1256-1257 ◽  
Author(s):  
J. Guarro ◽  
I. Pujol ◽  
E. Mayayo
Keyword(s):  
Drug Therapy ◽  
Amphotericin B ◽  
Fusarium Solani ◽  
Antifungal Agents ◽  
Antifungal Drugs ◽  
Infection Model ◽  
Disseminated Infection

ABSTRACT In the treatment of disseminated Fusarium infections, amphotericin B either alone or in combination with flucytosine and rifampin is the drug therapy most frequently used. The efficacy of these antifungal drugs was evaluated in a murine disseminated-infection model, with five strains of Fusarium solani. All the treatments were clearly ineffective.

scholarly journals Pre-Existing Liver Disease and Toxicity of Antifungals

2018 ◽  
Vol 4 (4) ◽  
pp. 133 ◽  
Author(s):  
Nikolaos Spernovasilis ◽  
Diamantis Kofteridis
Keyword(s):  
Decision Making ◽  
Liver Disease ◽  
Antifungal Agents ◽  
Dosage Adjustment ◽  
Fungal Infections ◽  
Drug Efficacy ◽  
Antifungal Drugs ◽  
Current Evidence ◽  
Comprehensive Review

Pre-existing liver disease in patients with invasive fungal infections further complicates their management. Altered pharmacokinetics and tolerance issues of antifungal drugs are important concerns. Adjustment of the dosage of antifungal agents in these cases can be challenging given that current evidence to guide decision-making is limited. This comprehensive review aims to evaluate the existing evidence related to antifungal treatment in individuals with liver dysfunction. This article also provides suggestions for dosage adjustment of antifungal drugs in patients with varying degrees of hepatic impairment, after accounting for established or emerging pharmacokinetic–pharmacodynamic relationships with regard to antifungal drug efficacy in vivo.

scholarly journals Bovine cartilage types VI and IX collagens. Characterization of their forms in vivo

1989 ◽  
Vol 262 (3) ◽  
pp. 753-761 ◽  
Author(s):  
S Ayad ◽  
A Marriott ◽  
K Morgan ◽  
M E Grant
Keyword(s):  
Molecular Mass ◽  
Proteinase Inhibitors ◽  
Guanidinium Chloride ◽  
Type Vi Collagen ◽  
Pepsin Digestion ◽  
Molecular Masses ◽  
Biosynthetic Studies ◽  
Bovine Cartilage

1. Collagens were extracted from bovine cartilage by 4 M-guanidinium chloride in the presence of proteinase inhibitors and identified by immunoblotting with specific anti-collagen sera. 2. The collagens retained their native conformations (shown by the resistance of their triple-helical domains to pepsin digestion), and the molecular masses of their component alpha-chains indicated that the chains were intact. 3. Type VI collagen was extracted as a large-molecular-mass disulphide-bonded aggregate composed of components of molecular mass 140 kDa and 200-240 kDa, and was therefore similar to type VI collagen identified in noncartilaginous tissues. Immunoblotting established the 200-240 kDa components as intact forms of the alpha 3(VI) chain. 4. Type IX collagen consisted of three clearly separable components of molecular mass 84 kDa, 72 kDa and 66 kDa, which were assigned to the alpha 1(IX)-, alpha 3(IX)- and alpha 2(IX)-chains respectively, and a large proportion of this collagen had no covalently bound glycosaminoglycan attached to the alpha 2(IX)-chain. 5. Differences between the type IX collagen extracted from bovine cartilage and that identified in biosynthetic studies on chick cartilage are discussed.

scholarly journals Establishment of a Novel Model of Onychomycosis in Rabbits for Evaluation of Antifungal Agents

2011 ◽  
Vol 55 (7) ◽  
pp. 3150-3155 ◽  
Author(s):  
Tsuyoshi Shimamura ◽  
Nobuo Kubota ◽  
Saori Nagasaka ◽  
Taku Suzuki ◽  
Hideki Mukai ◽  
...  
Keyword(s):  
Antifungal Agents ◽  
Histopathological Examination ◽  
Antifungal Drugs ◽  
Antifungal Treatment ◽  
Control Group ◽  
Recovery Method ◽  
Nail Lacquer ◽  
Significant Difference ◽  
Novel Model

ABSTRACTWe developed a novel model of onychomycosis in which we observed fungi in the deep layer of the nail, and we used the model to evaluate the efficacy of two topical antifungal drugs. To establish an experimental,in vivomodel of onychomycosis, we appliedTrichophyton mentagrophytesTIMM2789 to the nails of the hind limbs of rabbits that underwent steroid treatment. The nails were taken from the rabbits' feet at 0, 2, and 6 weeks after a 2-week infection. The localization of the fungi was evaluated histopathologically. Some fungi were seen to penetrate to the nail bed, and the infection rate in the sample at 0, 2, and 6 weeks after infection was 57, 87, and 93%, respectively. In addition, fungi proliferated and moved proximally into the nail plate in a manner that depended on the duration of infection. Second, using this model we evaluated antifungal efficacy both by the culture recovery method and histopathological examination. Two topical antifungal drugs, 8% ciclopirox nail lacquer and 5% amorolfine nail lacquer, were applied to the nail for 4 weeks in each group. On histopathological examination, two antifungal treatment groups showed no significant difference against the nontreated control group. However, there were a significantly low fungus-positive rate and intensity of the recovery of fungi on culture between antifungal treatment and nontreated control groups. We therefore suggest that we have established anin vivomodel of onychomycosis that is useful for the evaluation of the efficacy of antifungal agents.

In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates ofCandida spp.

1998 ◽  
Vol 42 (1) ◽  
pp. 161-163 ◽  
Author(s):  
F. Marco ◽  
M. A. Pfaller ◽  
S. Messer ◽  
R. N. Jones
Keyword(s):  
Amphotericin B ◽  
Antifungal Agents ◽  
Clinical Laboratory ◽  
Candida Krusei ◽  
Antifungal Drugs ◽  
National Committee ◽  
In Vitro Activity ◽  
Medical Centers

ABSTRACT Voriconazole (formerly UK-109,496) is a new monotriazole antifungal agent which has potent activity against Candida,Cryptococcus, and Aspergillus species. We investigated the in vitro activity of voriconazole compared to those of fluconazole, itraconazole, amphotericin B, and flucytosine (5FC) against 394 bloodstream isolates of Candida (five species) obtained from more than 30 different medical centers. MICs of all antifungal drugs were determined by the method recommended by the National Committee for Clinical Laboratory Standards using RPMI 1640 test medium. Overall, voriconazole was quite active against all the yeast isolates (MIC at which 90% of the isolates are inhibited [MIC90], ≤0.5 μg/ml). Candida albicans was the most susceptible species (MIC90, 0.06 μg/ml) andCandida glabrata and Candida krusei were the least (MIC90, 1 μg/ml). Voriconazole was more active than amphotericin B and 5FC against all species except C. glabrata and was also more active than itraconazole and fluconazole. For isolates of Candida spp. with decreased susceptibility to fluconazole and itraconazole MICs of voriconazole were also higher. Based on these results, voriconazole has promising antifungal activity and further in vitro and in vivo investigations are warranted.

scholarly journals Assessment and Optimizations of Candida albicansIn Vitro Biofilm Assays

2017 ◽  
Vol 61 (5) ◽  
Author(s):  
Matthew B. Lohse ◽  
Megha Gulati ◽  
Ashley Valle Arevalo ◽  
Adam Fishburn ◽  
Alexander D. Johnson ◽  
...  
Keyword(s):  
High Throughput Screening ◽  
Gene Deletion ◽  
Antifungal Drugs ◽  
Antifungal Compounds ◽  
Content Type ◽  
Advantages And Disadvantages ◽  
Different Types ◽  
Implanted Medical Devices

ABSTRACT Candida albicans biofilms have a significant medical impact due to their rapid growth on implanted medical devices, their resistance to antifungal drugs, and their ability to seed disseminated infections. Biofilm assays performed in vitro allow for rapid, high-throughput screening of gene deletion libraries or antifungal compounds and typically serve as precursors to in vivo studies. Here, we compile and discuss the protocols for several recently published C. albicans in vitro biofilm assays. We also describe improved versions of these protocols as well as novel in vitro assays. Finally, we consider some of the advantages and disadvantages of these different types of assays.

In-situ gel formulations of econazole nitrate: preparation and in-vitro and in-vivo evaluation

2011 ◽  
Vol 63 (10) ◽  
pp. 1274-1282 ◽  
Author(s):  
Esra Baloglu ◽  
Sinem Yaprak Karavana ◽  
Zeynep Ay Senyigit ◽  
Süleyha Hilmioglu-Polat ◽  
Dilek Yesim Metin ◽  
...  
Keyword(s):  
In Vivo Evaluation ◽  
In Situ Gel ◽  
Gel Formulations ◽  
Econazole Nitrate

Potential Uses of Vinegar as a Medicine and Related in vivo Mechanisms

2016 ◽  
Vol 86 (3-4) ◽  
pp. 127-151 ◽  
Author(s):  
Zeshan Ali ◽  
Zhenbin Wang ◽  
Rai Muhammad Amir ◽  
Shoaib Younas ◽  
Asif Wali ◽  
...  
Keyword(s):  
Chemical Structure ◽  
Review Paper ◽  
Heart Diseases ◽  
Folk Medicine ◽  
Active Role ◽  
Current Review ◽  
Different Types ◽  
Positive Effect

While the use of vinegar to fi ght against infections and other crucial conditions dates back to Hippocrates, recent research has found that vinegar consumption has a positive effect on biomarkers for diabetes, cancer, and heart diseases. Different types of vinegar have been used in the world during different time periods. Vinegar is produced by a fermentation process. Foods with a high content of carbohydrates are a good source of vinegar. Review of the results of different studies performed on vinegar components reveals that the daily use of these components has a healthy impact on the physiological and chemical structure of the human body. During the era of Hippocrates, people used vinegar as a medicine to treat wounds, which means that vinegar is one of the ancient foods used as folk medicine. The purpose of the current review paper is to provide a detailed summary of the outcome of previous studies emphasizing the role of vinegar in treatment of different diseases both in acute and chronic conditions, its in vivo mechanism and the active role of different bacteria.

Effects of Preloading of Stannous Compounds on the Distribution of 99mTc-Pertechnetate

1977 ◽  
Vol 16 (01) ◽  
pp. 26-29 ◽  
Author(s):  
D. D. Greenberg ◽  
P. Som ◽  
G. E. Meinken ◽  
D. F. Sacker ◽  
H. L. Atkins ◽  
...  
Keyword(s):  
Blood Cell ◽  
Red Blood Cell ◽  
Plasma Ratio ◽  
99Mtc Pertechnetate ◽  
Time Period ◽  
Stannous Ion ◽  
Distribution Studies

Summary 99mTc-pertechnetate distribution studies were performed in rabbits and mice following pretreatment between 5—336 hours with various routinely used stannous complexes (HSA, MAA, GHT, DTPA, PYPs) containing different amounts of Sn++ (0.17 —15.0 μ mg/kg). Beyond a concentration of 0.26 mg/kg of Sn++ an alteration in 99mTc-pertechnetate distribution was observed. The red blood cell was found to be the most prominent target. An in-vivo reduction of 99mTc-pertechnetate apparently occurred by the presence of stannous ion within the red blood cell. Preloading time period between 5—24 hours did not alter the uptake of RBC/plasma ratio. Beyond that period it decreased slowly and still persisted up to 2 weeks following pretreatment. RBC/ plasma ratio of 99mTcO4 - increased with increased Sn++ content of various commercially available pharmaceutical kits.

Sign in / Sign up

Export Citation Format

Share Document